Trial Profile
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Paclitaxel; Trastuzumab
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ATEMPT
- 01 Mar 2024 Results published in the Annals of Surgical Oncology
- 17 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 May 2024.
- 09 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.